Trial Profile
Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms SABR-ATAC
- 15 Sep 2023 Number of arms changed from 1 to 3. Allocation changed to Non-Randomized. Experimental arm (Phase 1) Fresolimumab 3 mg/kg and Fresolimumab 1 mg/kg added to study protocol.
- 02 Feb 2022 Status changed from active, no longer recruiting to completed.
- 12 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.